Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06042920 · ClinicalTrials.gov registry record · Phase 4
A Study to Evaluate Effectiveness and Safety of Deucravacitinib in Participants With Non-Pustular Palmoplantar and Genital Psoriasis
A Phase 4 study, sponsored by Bristol-Myers Squibb.
- Terminated
- Registry status
- Phase 4
- Development phase
- 130
- Enrollment target
NCT06042920 is a Phase 4 study that was terminated before completion, run by Bristol-Myers Squibb. The registered enrollment target is 130 participants.
The verdict
NCT06042920, a Phase 4 study, was terminated before completion, sponsored by Bristol-Myers Squibb.
- TERMINATED
- Registry status
- Phase 4
- Development phase
- 130 participants
- Enrollment target
Study Summary
The purpose of this study is to measure the safety and effectiveness of deucravatinib in participants with non-pustular palmoplantar psoriasis and genital psoriasis.
Interventions
- DRUG Placebo
- DRUG Deucravacitinib
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 130 participants |
| Start Date | 2023-10-09 |
| Est. Completion | 2025-04-25 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06042920
The ClinicalTrials.gov registry entry for NCT06042920 describes a study currently listed as terminated, categorized as Phase 4. The registered enrollment target is 130 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Bristol-Myers Squibb, which has 1,025 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT06042920 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT06042920 about?
NCT06042920 is a clinical study titled "A Study to Evaluate Effectiveness and Safety of Deucravacitinib in Participants With Non-Pustular Palmoplantar and Genital Psoriasis". The purpose of this study is to measure the safety and effectiveness of deucravatinib in participants with non-pustular palmoplantar psoriasis and genital psoriasis.
What is the current status of trial NCT06042920?
This trial is currently terminated. It is a Phase 4 study. The enrollment target is 130 participants. The study started on 2023-10-09. Estimated completion is 2025-04-25.
What interventions are being tested in trial NCT06042920?
The interventions under investigation include: Placebo (DRUG), Deucravacitinib (DRUG).
Who is sponsoring clinical trial NCT06042920?
This trial is sponsored by Bristol-Myers Squibb, which has 1,025 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.